Cencora, Inc. (NYSE:COR) Position Increased by Royal Bank of Canada

Royal Bank of Canada raised its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 14.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,206,002 shares of the company's stock after acquiring an additional 155,453 shares during the quarter. Royal Bank of Canada owned approximately 0.62% of Cencora worth $270,964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Whittier Trust Co. lifted its stake in Cencora by 0.6% in the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after purchasing an additional 44 shares in the last quarter. Shepherd Financial Partners LLC boosted its stake in Cencora by 0.9% during the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock worth $1,223,000 after buying an additional 46 shares during the last quarter. WASHINGTON TRUST Co raised its holdings in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after acquiring an additional 46 shares during the period. JFS Wealth Advisors LLC increased its position in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares during the last quarter. Finally, Cullen Frost Bankers Inc. raised its stake in Cencora by 1.1% during the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock worth $1,003,000 after purchasing an additional 47 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Evercore ISI raised their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. UBS Group lifted their price objective on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Finally, Wells Fargo & Company increased their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $301.18.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. The trade was a 4.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. The trade was a 24.54% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is currently owned by corporate insiders.

Cencora Trading Down 0.5%

Shares of Cencora stock traded down $1.50 during trading hours on Wednesday, hitting $291.43. The company's stock had a trading volume of 942,182 shares, compared to its average volume of 1,545,503. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market capitalization of $56.49 billion, a PE ratio of 41.46, a P/E/G ratio of 1.31 and a beta of 0.60. The business has a fifty day moving average of $281.28 and a 200 day moving average of $256.26. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $309.35.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The business had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business's revenue was up 10.3% on a year-over-year basis. During the same period last year, the business earned $3.80 EPS. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date is Friday, May 16th. Cencora's payout ratio is currently 25.52%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.